Results 211 to 220 of about 99,547,245 (298)

Cross‐Cancer Profiling of CDH1 Reveals Context‐Dependent EMT Decoupling, Immune Heterogeneity, and Prognostic Variability in Epithelial Cancers

open access: yesComputational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Cadherin 1 (CDH1) encodes E‐cadherin, a key epithelial adhesion molecule traditionally associated with tumor suppression and epithelial–mesenchymal transition (EMT). However, its roles across cancers remain incompletely understood, particularly within multilayer regulatory contexts involving genomic, epigenetic, transcriptional, and immune ...
Md. Abdur Rahman   +2 more
wiley   +1 more source

The Place of Therapeutic Apheresis in Severe Immune‐Related Adverse Events: A Scoping Review of Literature

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 6, December 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized the management of patients with cancer. However, they can induce breakdowns in immunologic tolerance, leading to autoimmune diseases, or immune related adverse events (irAEs). These irAEs can sometimes be life threatening, requiring aggressive management, such as immunosuppressant (IS) or
C. Vuillet   +36 more
wiley   +1 more source

Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC. [PDF]

open access: yesFront Immunol
Gumuzio J   +10 more
europepmc   +1 more source

Comparison of Gene Enrichment Between Prostate Tissue and Urine for Non‐Invasive Biomarker Development

open access: yesThe Prostate, Volume 86, Issue 16, Page 1653-1663, Deceamber 2026.
ABSTRACT Background For prostate cancer (PCa), early diagnosis and biomarker‐based patient stratification can improve clinical decision‐making and post‐treatment prognosis. PCa biomarkers are best validated in tissue following comprehensive histopathologic review; however, urinary biomarkers can be obtained non‐invasively and are therefore safer and ...
Yuandong Xing   +11 more
wiley   +1 more source

First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies. [PDF]

open access: yesESMO Open
Ekström-Rydén V   +7 more
europepmc   +1 more source

Assessment of Clinical and Immunological Factors of Local Recurrence in Canine Soft Tissue Sarcoma

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 4, Page 859-875, December 2026.
ABSTRACT Canine soft tissue sarcomas (STSs) are locally invasive tumours, making local recurrence a major clinical challenge. Time to recurrence (TTR) and associated immune factors remain poorly characterized. This study aimed to characterize the immune microenvironment of canine STS and identify factors associated with TTR.
Kazuki Mizuta   +2 more
wiley   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy